Form 4: Pulse Biosciences Director Receives Stock Option Grant

Director Manmeet Singh Soni was granted 30,000 stock options in Pulse Biosciences, Inc. as part of a compensation package.

Summary

• Director Manmeet Singh Soni received a grant of 30,000 stock options for Pulse Biosciences, Inc. (PLSE) common stock.
• The options have an exercise price of $26.89 per share.
• The options vest in equal monthly installments over a one-year period starting July 11, 2026.
• The options expire on June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant signal regarding company performance.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility could impact the value of the options relative to the exercise price.
• Continued service requirement for vesting creates dependency on the director's ongoing tenure.

Future Outlook

The options vest over a one-year period, indicating a short-term retention and incentive structure for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure alignment between board members and shareholders.

Comparison to Industry Standards

• The use of monthly vesting over one year is a standard practice for non-employee director compensation in mid-cap biotech firms.
• The exercise price reflects the market value at the time of the grant, consistent with SEC and tax compliance requirements.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first installment of options on July 11, 2026.

Key Dates

Keywords

Pulse Biosciences, PLSE, Form 4, Stock Options, Insider Trading, Director Compensation